ANTENGENE-B

6996.HK opened at HKD 4.05 and quickly rallied to HKD 4.10 in the morning session, closing up 5.40%, driven primarily by the company's swing to profitability in its 2026 interim results. Key financials showed Q2 2026 revenue surged 917.3% YoY to HKD 296 million, net profit reached HKD 124.8 million (+398.68% YoY), and EPS was HKD 0.1962 (+391.24% YoY). The company had previously guided an interim profit of up to HKD 238 million, and subsequent announcements of a USD 60 million upfront payment from UCB and HREC approval for the Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseases provided further catalysts. However, the stock still trades 49.75% below its 52-week high of HKD 8.16, with YTD gain of only 4.86%, and the PE of 45.01x and PB of 2.64x suggest lingering skepticism about the sustainability of the turnaround.

Antengene closed at HKD 3.89, down 0.38% for the session, with a notable intraday surge to HKD 4.185 in the morning before fading, and traded in a narrow HKD 3.87-3.91 range in the afternoon. The company's 2026 interim results showed a first-ever net profit of RMB 216 million, with revenue surging over 9x YoY to RMB 513 million, primarily driven by the upfront payment from its UCB licensing deal. The stock remains 52.3% below its 52-week high of HKD 8.16, trades below the 20-day MA of HKD 4.098 but above the 60-day MA of HKD 3.914, with a YTD decline of 0.51%.

Antengene opened lower and continued to decline during the morning session, falling from a high of HKD 4.020 to a low of HKD 3.815, down 5.1% with a turnover of approximately HKD 571,000, significantly underperforming the broader market. The drop was triggered by a series of events including the CFO's resignation, board changes, and a USD 60 million upfront payment from UCB, which markets had already priced in, leaving a lack of fresh catalysts. The latest quarterly revenue of HKD 29.0 million surged 74.9% YoY, but net loss of HKD 90.5 million widened 11.8% YoY, with a deeply negative net profit margin, reflecting high R&D spending and no turnaround yet. The stock, at HKD 3.815, trades below both its MA20 of HKD 4.111 and MA60 of HKD 3.917, and is 53.3% below its 52-week high of HKD 8.16, with YTD decline of 2.4%, indicating a weak technical position. However, the company recently announced a HK$50 million share buyback plan and a projected interim profit turnaround, offering some positive signals.

Antengene opened higher at HKD 3.87 and quickly rose to HKD 3.94 before settling at HKD 3.93 in the morning session, up 4.8% from the previous close of HKD 3.75, driven by its interim profit turnaround guidance with net profit up to RMB 238 million, a USD 60 million upfront payment from UCB, and a HK$ 50 million share buyback plan with consecutive repurchases. At HKD 3.93, the stock remains 51.8% below its 52-week high of HKD 8.16 but has recovered above the 60-day MA of HKD 3.924, though still below the 20-day MA of HKD 4.121, with a YTD gain of 0.5%. However, Q4 2025 net loss of HKD 90.5 million widened 11.8% YoY, and revenue of HKD 29 million, while up 74.9% YoY, remains modest, indicating the fundamental turnaround is still in its early stages.

Antengene (6996.HK) surged to an intraday high of HKD 4.03 during the morning session before sliding sharply, closing at HKD 3.72, down 4.98% from the previous close of HKD 3.915. The decline was driven by profit-taking after the company's interim profit guidance (net profit up to RMB 238M) was priced in. The stock opened over 3% higher but reversed sharply, resulting in an intraday range of 8.1%, with thin volume of 1.23 million shares (turnover rate 0.18%). Despite revenue growth of 74.9% YoY to approximately HKD 29M, net loss widened 11.76% to -HKD 90.5M, with a net margin still at -312%. The stock now trades below both its 20-day (HKD 4.124) and 60-day (HKD 3.931) moving averages, 54.41% below its 52-week high of HKD 8.16, though 34.78% above the low of HKD 2.76. However, recent licensing deals (UCB, K2 Therapeutics) and ongoing share buybacks may bolster medium-term sentiment.